Can you take Roflumilast with Thymoglobulin?
1 drug interaction and 9 additional warnings found for the following 2 drugs:
- roflumilast
- Thymoglobulin (anti-thymocyte globulin (rabbit))
Drug interactions
Moderate drug interactions
Moderate:
anti-thymocyte globulin (rabbit) roflumilast
Applies to: Thymoglobulin (anti-thymocyte globulin (rabbit)) and roflumilast
Using roflumilast together with anti-thymocyte globulin (rabbit) may have additive effects on the immune system, possibly increasing the risk of infections or immunologic disorders. You may not be able to use roflumilast if you have a serious infection, cancer, or an immune-based disorder such as HIV infection, multiple sclerosis, or lupus. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Minor food/lifestyle interactions
Minor:
roflumilast Food/Lifestyle
Applies to: roflumilast
Information for this minor interaction is available on the professional version.
Disease interactions
8 potential interactions Applies to: 8 conditions, including Depression, Anxiety and Stress, Liver Disease, Infection, and Immunodeficiency.
Anxiety and Stress
Moderate:
roflumilast
Roflumilast has a moderate potential interaction with Anxiety and Stress.
The use of roflumilast is associated with an increase in psychiatric adverse reactions. Instances of suicidal ideation and behavior, including completed suicide, have been observed in clinical trials. Before using roflumilast in patients with a history of depression and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment in all patients. Close monitoring for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes is recommended.
Bone Marrow Depression/Low Blood Counts
Major:
Thymoglobulin
The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.
The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.
Depression
Moderate:
roflumilast
Roflumilast has a moderate potential interaction with Depression.
The use of roflumilast is associated with an increase in psychiatric adverse reactions. Instances of suicidal ideation and behavior, including completed suicide, have been observed in clinical trials. Before using roflumilast in patients with a history of depression and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment in all patients. Close monitoring for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes is recommended.
Failure to Thrive
Moderate:
roflumilast
Roflumilast has a moderate potential interaction with Failure to Thrive.
Weight loss is a common adverse reaction with the use of roflumilast. Patients treated with roflumilast should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, weight loss should be evaluated, and discontinuation of treatment should be considered. Care should be exercised when using this agent in patients at risk of weight loss.
Immunodeficiency
Major:
Thymoglobulin
The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Immunodeficiency.
The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.
Infection
Major:
Thymoglobulin
The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Infection.
The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.
Liver Disease
Major:
roflumilast
Roflumilast has a major potential interaction with Liver Disease.
Roflumilast is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). Roflumilast is extensively metabolized via Phase I (cytochrome P450) and Phase II (conjugation) reactions. Clinicians should consider the risk-benefit of administering roflumilast to patients with mild liver impairment (Child-Pugh A).
Vaccination
Major:
Thymoglobulin
The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Vaccination.
Patients recently treated with anti-thymocyte globulin [rabbit] should not receive immunizations with live viral vaccines.
Report options
More resources
roflumilast
A total of 402 drugs are known to interact with roflumilast.
- Roflumilast is in the drug class selective phosphodiesterase-4 inhibitors.
- Roflumilast is used to treat the following conditions:
Thymoglobulin
A total of 180 drugs are known to interact with Thymoglobulin.
- Thymoglobulin is in the drug class selective immunosuppressants.
- Thymoglobulin is used to treat Renal Transplant.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.